<p><strong>Children</strong>: No formal pharmacokinetic study has been conducted in children.<br />
<br />
<strong>Elderly</strong>: In the elderly, the half-life of piracetam is increased and the increase is related to the decrease in renal function in this population (see Section Dosage and Administration).<br />
<br />
<strong>Renal impairment</strong>: Piracetam clearance is correlated to creatinine clearance. It is therefore recommended to adjust the daily dose of piracetam based on creatinine clearance in patients with renal impairment&nbsp;<br />
<br />
<strong>Hepatic impairment</strong>: The influence of hepatic impairment on the pharmacokinetics of piracetam has not been evaluated. Because 80 to 100% of the dose is excreted in the urine as unchanged drug, hepatic impairment solely would not be expected to have a significant effect on piracetam elimination.</p>